In a bold move promising to revolutionise healthcare, Novo Nordisk and Septerna have forged an extraordinary alliance, aimed at exploiting cutting-edge science to combat obesity and other cardiometabolic illnesses. This collaboration promises to push the frontiers of medicine, specifically targeting G protein-coupled receptor (GPCR) drug discovery, with an aim to develop multiple oral small molecule therapies.\Notably, the partnership is poised to capitalise on the shared strengths of both companies. Novo Nordisk, with its rich history in obesity and diabetes innovation, is a giant in the scientific realm, while Septerna’s capabilities in GPCR drug discovery presents significant potential.
14-05-2025
OKYO Pharma, an ophthalmology-centred bio-pharmaceutical company on NASDAQ, is celebrating the U.S. Food and Drug Administration’s fast-track approval of its innovative drug Urcosimod. Previously known as OK-101, this promising drug is set to address the severe and chronic pain caused by Neuropathic Corneal Pain (NCP), for which there is currently no FDA-approved therapy.
The FDA’s fast track and priority review process is designed to facilitate the swift development and review of novel treatments that promise to address significant unmet medical needs in treating serious conditions.
01-05-2025